Heart valve allografts
This article was originally published in The Gray Sheet
Executive SummaryWashington Legal Foundation files suit in the U.S. district court for the District of Columbia on March 4, seeking to enjoin FDA from enforcing its policy of requiring premarket approval applications for human heart valve allografts. WLF argues that the allografts do not fall within the definition of medical devices in the 1976 device law. In May, the group petitioned FDA to withdraw its June 1991 final rule requiring PMAs for the valves. That petition was denied on Feb. 8.
You may also be interested in...
Biogen’s “recipe-driven qualification” knowledge management program standardizes data collection and reporting in the laboratory, with efficiency gains of 66%.
Less-invasive technologies to treat benign prostatic hyperplasia are fast becoming viable alternatives to medication and surgery. Landmark studies of newer techniques have led the American Urological Association to update its guidelines.